AU Patent

AU2023276826A1 — Aprocitentan for the treatment of hypertension

Assigned to Idorsia Pharmaceuticals Ltd · Expires 2025-01-09 · 1y expired

What this patent protects

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide: Formula (I) and its use as endothelin receptor antagonist in a method of treating hypertension including resistant hypertension in a s…

USPTO Abstract

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide: Formula (I) and its use as endothelin receptor antagonist in a method of treating hypertension including resistant hypertension in a subject in need thereof, said method comprising administering to the subject a pharmaceutical composition comprising a clinically proven effective amount of aprocitentan, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023276826A1
Jurisdiction
AU
Classification
—
Expires
2025-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Idorsia Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.